Atara Biotherapeutics, Inc.
ATRA
|
$0.6755
-2.34%
-2.4%
1.6M
|
Health Technology
(0.0% 1d) (-1.3% 1m) (-78.3% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (58.73% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 80,627,160
http://www.atarabio.com
Sec Filling | Patents | 393 employees
(US) Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
cancer autoimmunity msa
add to watch list Paper trade email alert is off
Press-releases
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 10.45%
H: 11.61%
C: -7.38%
ata3219 fda lupus clearance application therapy
Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies
Published: 2024-02-23 (Crawled : 10:00) - prnewswire.com
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 1.64%
H: 1.71%
C: -7.96%
rare
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Published: 2024-02-14 (Crawled : 15:30) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 6.48%
H: 0.0%
C: -6.07%
ata3219 drug lupus treatment application submission
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
Published: 2024-01-08 (Crawled : 15:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -0.29%
H: 29.43%
C: 25.65%
million direct offering
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -7.38%
H: 7.89%
C: 6.31%
ata3431 positive preclinical meeting
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Published: 2023-11-01 (Crawled : 15:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 3.1%
H: 0.75%
C: -5.26%
cel partnership global financial results
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
Published: 2023-09-19 (Crawled : 21:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 0.0%
H: 3.21%
C: 1.28%
cel fda agreement
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
Published: 2023-08-31 (Crawled : 22:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -0.68%
H: 6.21%
C: 0.69%
conference cell biopharma
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
Published: 2023-06-05 (Crawled : 14:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 0.0%
H: 2.92%
C: 1.3%
cel asco
Multicancer Screening Global Market Report 2023: Sector to Reach $7.78 Billion by 2032 at a 15% CAGR
Published: 2023-05-29 (Crawled : 19:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.34%
H: 0.5%
C: -1.83%
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
|
| O: -0.35%
H: 0.43%
C: -1.35%
NVTA | $0.019 0.0% 22M
|
Health Services
|
| O: 1.89%
H: 3.7%
C: -2.78%
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
|
| O: 0.34%
H: 0.58%
C: -2.49%
A | $132.73 0.22% 0.0% 1.3M
|
Health Technology
|
| O: -0.34%
H: 1.08%
C: -1.9%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: 0.18%
H: 3.02%
C: -0.31%
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: 0.15%
H: 1.16%
C: -0.86%
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: 2.24%
H: 3.41%
C: -0.17%
EXAS | $60.97 -3.95% -4.12% 2.2M
|
Health Technology
|
| O: 0.67%
H: 2.45%
C: -1.72%
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -0.56%
H: 6.25%
C: -7.95%
report reach global market
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10